Evidence map›Paper›PMID 39117964›Full record

Trial reportNeurocritical care2024

Efficacy and Safety of Early Treatment with Glibenclamide in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized Controlled Trial.

Qing Lin, Dawei Zhou, Jiawei Ma, Jingwei Zhao, Guangqiang Chen, Lei Wu, Tong Li, Shangfeng Zhao, Honglin Wen, Huixian Yu and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Neurocritical care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05137678 (The Safety and Effectiveness of Glibenclamide in the Treatment of Aneurysm Subarachnoid Hemorrhage（aSAH）), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05137678 phase4unknown statusnot on this map

The Safety and Effectiveness of Glibenclamide in the Treatment of Aneurysm Subarachnoid Hemorrhage（aSAH）: a Randomized Controlled Clinical Study

TypeinterventionalSponsorBeijing Tiantan HospitalRan2021 to 2022Enrolled110ConditionsSubarachnoid HemorrhageArmsglibenclamide
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qing LinDepartment of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Dawei ZhouDepartment of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Jiawei MaDepartment of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring Road West, Fengtai District, Beijing, China.
Jingwei ZhaoDepartment of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring Road West, Fengtai District, Beijing, China.
Guangqiang ChenDepartment of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring Road West, Fengtai District, Beijing, China.
Lei WuDepartment of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring Road West, Fengtai District, Beijing, China.
Tong LiDepartment of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Shangfeng ZhaoDepartment of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Honglin WenClinical Laboratory Center, Beijing Hospital of Traditional Chinese Medicine, Beijing, China.
Huixian YuDepartment of Rehabilitation, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Shaolan ZhangDepartment of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring Road West, Fengtai District, Beijing, China.
Kai GaoDepartment of Critical Care Medicine, Central Hospital of Dalian University of Technology, Dalian, China.
Rongli YangDepartment of Critical Care Medicine, Central Hospital of Dalian University of Technology, Dalian, China.
Guangzhi ShiDepartment of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring Road West, Fengtai District, Beijing, China. shiguangzhi@bjtth.org.ORCID 0000-0003-4189-5800

Funding

Yangfan Project for Key Medical Programs from the Hospital Authority of Beijing ZYLX202109
6 · The paper itself

Abstract

backgroundThis study aims to investigate the efficacy and safety of glibenclamide treatment in patients with acute aneurysmal subarachnoid hemorrhage (aSAH).

methodsThe randomized controlled trial was conducted from October 2021 to May 2023 at two university-affiliated hospitals in Beijing, China. The study included patients with aSAH within 48 h of onset, of whom were divided into the intervention group and the control group according to the random number table method. Patients in the intervention group received glibenclamide tablet 3.75 mg/day for 7 days. The primary end points were the levels of serum neuron-specific enolase (NSE) and soluble protein 100B (S100B) between the two groups. Secondary end points included evaluating changes in the midline shift and the gray matter-white matter ratio, as well as assessing the modified Rankin Scale scores during follow-up. The trial was registered at ClinicalTrials.gov (identifier NCT05137678).

resultsA total of 111 study participants completed the study. The median age was 55 years, and 52% were women. The mean admission Glasgow Coma Scale was 10, and 58% of the Hunt-Hess grades were no less than grade III. The baseline characteristics of the two groups were similar. On days 3 and 7, there were no statistically significant differences observed in serum NSE and S100B levels between the two groups (P > 0.05). The computer tomography (CT) values of gray matter and white matter in the basal ganglia were low on admission, indicating early brain edema. However, there were no significant differences found in midline shift and gray matter-white matter ratio (P > 0.05) between the two groups. More than half of the patients had a beneficial outcome (modified Rankin Scale scores 0-2), and there were no statistically significant differences between the two groups. The incidence of hypoglycemia in the two groups were 4% and 9%, respectively (P = 0.439).

conclusionsTreating patients with early aSAH with oral glibenclamide did not decrease levels of serum NSE and S100B and did not improve the poor 90-day neurological outcome. In the intervention group, there was a visible decreasing trend in cases of delayed cerebral ischemia, but no statistically significant difference was observed. The incidence of hypoglycemia did not differ significantly between the two groups.

Indexed as

GlyburidePhosphopyruvate HydrataseS100 Calcium Binding Protein beta SubunitSubarachnoid HemorrhageAdultAgedFemaleHumansHypoglycemic AgentsMaleMiddle AgedTreatment OutcomeGlyburideHypoglycemic AgentsPhosphopyruvate HydrataseS100B protein, humanS100 Calcium Binding Protein beta SubunitAneurysmal subarachnoid hemorrhageBrain edemaGlibenclamideSUR1-TRPM4 channel

Identifiers

PMID39117964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.